|
Gene: ZIM3 |
Gene summary for ZIM3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZIM3 | Gene ID | 114026 |
Gene name | zinc finger imprinted 3 | |
Gene Alias | ZNF264 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96PE6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114026 | ZIM3 | HCC1 | Human | Liver | HCC | 1.08e-05 | 5.88e-01 | 0.5336 |
114026 | ZIM3 | HCC2 | Human | Liver | HCC | 4.05e-12 | 9.81e-01 | 0.5341 |
114026 | ZIM3 | HCC5 | Human | Liver | HCC | 3.09e-02 | 6.24e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZIM3 | SNV | Missense_Mutation | c.1201T>C | p.Phe401Leu | p.F401L | Q96PE6 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZIM3 | SNV | Missense_Mutation | novel | c.1065A>C | p.Lys355Asn | p.K355N | Q96PE6 | protein_coding | deleterious(0.02) | probably_damaging(0.924) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | novel | c.816T>G | p.Ile272Met | p.I272M | Q96PE6 | protein_coding | deleterious(0.01) | probably_damaging(0.934) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | novel | c.1363G>T | p.Ala455Ser | p.A455S | Q96PE6 | protein_coding | deleterious(0.02) | probably_damaging(0.919) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | rs539722568 | c.1403G>T | p.Arg468Ile | p.R468I | Q96PE6 | protein_coding | deleterious(0) | benign(0.009) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | rs866999224 | c.828G>T | p.Lys276Asn | p.K276N | Q96PE6 | protein_coding | deleterious(0) | benign(0.375) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | novel | c.89G>A | p.Arg30Lys | p.R30K | Q96PE6 | protein_coding | tolerated(0.42) | benign(0.02) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ZIM3 | SNV | Missense_Mutation | novel | c.394N>T | p.Asp132Tyr | p.D132Y | Q96PE6 | protein_coding | deleterious(0.03) | benign(0.132) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | c.103N>A | p.Asp35Asn | p.D35N | Q96PE6 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZIM3 | SNV | Missense_Mutation | rs752041536 | c.1369N>A | p.Ala457Thr | p.A457T | Q96PE6 | protein_coding | tolerated(0.27) | benign(0.203) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |